Edition:
United States

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

10.20USD
3:59pm EST
Change (% chg)

$0.25 (+2.51%)
Prev Close
$9.95
Open
$10.03
Day's High
$10.29
Day's Low
$9.88
Volume
80,652
Avg. Vol
66,003
52-wk High
$17.33
52-wk Low
$8.86

Chart for

About

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on... (more)

Overall

Beta: --
Market Cap(Mil.): $403.27
Shares Outstanding(Mil.): 40.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis

* SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS

Dec 04 2017

BRIEF-Seres Therapeutics Q2 net loss $28 million

* Seres therapeutics reports second quarter 2017 financial results and provides update on operational progress

Aug 03 2017

BRIEF-Seres Therapeutics appoints Willard Dere to Board of Directors

* Seres Therapeutics strengthens board of directors with appointment of Willard Dere, M.D., former Amgen Chief Medical Officer Source text for Eikon: Further company coverage:

Jul 10 2017

Earnings vs. Estimates